Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 11/2013

01-07-2013 | Adis Drug Evaluation

Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome

Author: Mark Sanford

Published in: Drugs | Issue 11/2013

Login to get access

Abstract

Mirabegron (YM178, Myrbetriq™, Betanis®, Betmiga™) is a β3-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome. In three 12-week, randomized, double-blind, placebo-controlled, multinational trials in patients with overactive bladder syndrome, oral mirabegron 25 or 50 mg once daily significantly reduced the adjusted mean number of incontinence episodes per 24 h (in patients with incontinence at baseline) and the adjusted mean number of micturition episodes per 24 h (in full trial populations) [coprimary endpoints]. Across trials, mirabegron 50 mg once daily also consistently significantly reduced urgency episodes and increased the volume of urine voided per micturition, generally in association with improved health-related quality of life (HR-QOL) and treatment satisfaction. Based on descriptive analyses from a 12-month trial, once-daily mirabegron 50 mg and tolterodine extended-release (ER) 4 mg were both efficacious in reducing urinary symptoms and improving HR-QOL. Mirabegron was generally well tolerated in the trials. Over 12 weeks, the adverse event rate with mirabegron 50 mg once daily was similar to that with placebo. During 12 months of treatment, 2.8 % of mirabegron 50 mg once daily recipients reported dry mouth compared with 8.6 % with tolterodine ER 4 mg once daily recipients. Mirabegron 50 mg once daily carries a low risk of QT interval prolongation. Thus, mirabegron is an efficacious new treatment for overactive bladder syndrome with a favourable tolerability profile.
Literature
1.
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMed
2.
Wagg A, Majumdar A, Toozs-Hobson P, et al. Current and future trends in the management of overactive bladder. Int Urogynecol J. 2007;18(1):81–94.CrossRef
3.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–15.PubMedCrossRef
4.
Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6.PubMedCrossRef
5.
Wein AJ, Chapple C. Overactive bladder in clinical practice. London: Springer; 2012.CrossRef
6.
Marinkovic SP, Rovner ES, Moldwin RM, et al. The management of overactive bladder syndrome. BMJ. 2012;344(7853):38–44.
7.
Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004;64(15):1643–56.PubMedCrossRef
8.
9.
10.
11.
12.
13.
Nitti V, Rosenberg S, Mitcheson D, et al. Urodynamic safety of the potent and selective beta3-adrenoceptor agonist, mirabegron, in males with lower urinary tract symptoms and bladder outlet obstruction [abstract no. POD-03.05]. Urology. 2012;80(3 Suppl. 1):S10.
14.
Chapple CR, Amarenco G, López Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. BLOSSOM Investigator Group. Neurourol Urodyn. 2013. doi:10.​1002/​nau.​22373.
15.
16.
Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo- and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706.PubMedCrossRef
17.
Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a Β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34(10):2144–60.PubMedCrossRef
18.
Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective Β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–24.PubMedCrossRef
19.
Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a Β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838–50.PubMed
20.
Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Invest. 2012;31(1):11–23.
21.
van Gelderen EM, Li Q, Meijer J, et al. An exploratory comparison of the single dose pharmacokinetics of the beta3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers [abstract no. PIII-65]. Clin Pharmacol Ther. 2009;85 Suppl.:S88.
22.
Krauwinkel WJ, van Gelderen EM, Groen MJ. An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects [abstract no. PIII-65]. In: 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 17-20 Mar 2010; Atlanta.
23.
Sawamoto T, Lee J, Alak A, et al. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects [abstract no. PI-43]. Clin Pharmacol Ther. 2011;89 Suppl.:S21.
24.
Sawamoto T, Lee J, Cao Y, et al. Phase I, open-label, drug interaction study to evaluate the effect of repeat doses of rifampin on the single-dose pharmacokinetics of mirabegron (YM178) in healthy adult subjects [abstract no. PI-44]. Clin Pharmacol Ther. 2011;89 Suppl.:S21–2.
25.
Veltkamp S, van Gelderen M, Schaddelee M, et al. Clinical study into the pharmacokinetic, pharmacodynamic and safety interaction of the novel Β3-adrenoceptor agonist mirabegron and metformin in healthy subjects [abstract no. WP107]. In: 9th Congress of the European Association for Clinical Pharmacology and Therapeutics; 12–15 Jul 2009; Edinburgh.
26.
Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a Β3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.PubMedCrossRef
27.
Nitti V, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.PubMedCrossRef
28.
Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013. doi:10.​1016/​j.​urology.​2013.​02.​077.
29.
Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a Β3-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.PubMedCrossRef
30.
Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32.PubMedCrossRef
31.
Khullar V, Cambronero J, Angulo J, et al. Age-related efficacy of the B3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised phase III studies in patients aged ≥65 years [abstract no. 331]. In: 42nd Annual Meeting of the International Continence Society; Oct 15–19 2012; Beijing.
32.
Nitti V, Herschorn S, Khullar V, et al. Efficacy of the selective B3-adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB) who discontinued prior antimuscarinic therapy due to insufficient effect: pooled analysis of three randomised phase III studies [abstract no. 351]. In: 37th Annual Meeting of the International Urogynecological Association; Sep 4–8 2012; Brisbane.
33.
Nitti V, Herschorn S, Auerbach S, et al. The potent and selective Β3-adrenoceptor agonist mirabegron improves patient-reported outcomes in overactive bladder: results from two phase III studies [abstract no. 68]. Neurourol Urodyn. 2012;31(6):813–5.
34.
van Kerrebroeck P, Barkin J, Castro-Diaz D, et al. Randomised, double-blind, placebo-controlled phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once-daily in overactive bladder (OAB) [abstract no. 359 plus poster]. In: 42nd Annual Meeting of the International Continence Society; 15–19 October 2012; Beijing, China.
35.
Astellas Pharma Europe, Ltd. A double-blind, randomized, parallel group, multicentre study to evaluate the efficacy and safety of mirabegron compared to solifenacin in subjects with overactive bladder (OAB) treated with antimuscarinics and dissatisfied due to lack of efficacy. 2012. http://​clinicaltrials.​gov/​show/​NCT01638000. Accessed 7 Feb 2013.
36.
Metadata
Title
Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome
Author
Mark Sanford
Publication date
01-07-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 11/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0086-3

Other articles of this Issue 11/2013

Drugs 11/2013 Go to the issue

Review Article

Adverse Effects of Immunosuppressant Drugs upon Airway Epithelial Cell and Mucociliary Clearance: Implications for Lung Transplant Recipients

Adis Drug Evaluation

Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma

R&D Insight Report

Trametinib: First Global Approval

Adis Drug Evaluation

Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years

Review Article

Meningococcal Vaccines: Current Issues and Future Strategies

Systematic Review

Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials